tiprankstipranks
Advertisement
Advertisement

BEAM Stock Latest News

JonesResearch upgrades ‘fast-follower’ Korro Bio to Buy
The FlyJonesResearch upgrades ‘fast-follower’ Korro Bio to Buy
2d ago
WVE
BEAM
Beam Therapeutics reports Q1 EPS (91c), consensus ($1.01)
PremiumThe Fly
Beam Therapeutics reports Q1 EPS (91c), consensus ($1.01)
3d ago
BEAM
Beam Therapeutics rises 10.7%
PremiumThe Fly
Beam Therapeutics rises 10.7%
13d ago
BEAM
Beam Therapeutics rises 10.8%
PremiumThe Fly
Beam Therapeutics rises 10.8%
13d ago
BEAM
Beam Therapeutics: Compelling BEAM-302 Data and Manageable Safety Profile Underpin Buy Rating and Favorable Risk‑Reward
PremiumRatings
Beam Therapeutics: Compelling BEAM-302 Data and Manageable Safety Profile Underpin Buy Rating and Favorable Risk‑Reward
1M ago
BEAM
Beam Therapeutics’ risto-cel shows efficacy in Sickle Cell Disease trial
PremiumThe FlyBeam Therapeutics’ risto-cel shows efficacy in Sickle Cell Disease trial
1M ago
BEAM
Beam Therapeutics price target raised to $68 from $64 at Citi
Premium
The Fly
Beam Therapeutics price target raised to $68 from $64 at Citi
2M ago
BEAM
Clear Street sees buying opportunity for Beam Therapeutics after study update
Premium
The Fly
Clear Street sees buying opportunity for Beam Therapeutics after study update
2M ago
BEAM
Beam Therapeutics: BEAM-302’s Differentiated AATD Profile and Accelerated Path Support Buy Rating and $80 Target
PremiumRatings
Beam Therapeutics: BEAM-302’s Differentiated AATD Profile and Accelerated Path Support Buy Rating and $80 Target
2M ago
BEAM
Beam Therapeutics announces safety, efficacy data from BEAM-302 trial
PremiumThe Fly
Beam Therapeutics announces safety, efficacy data from BEAM-302 trial
2M ago
BEAM
Beam Therapeutics Restructures Base-Editing Licensing After Bio Palette Exit
PremiumCompany Announcements
Beam Therapeutics Restructures Base-Editing Licensing After Bio Palette Exit
2M ago
8K
BEAM
Beam Therapeutics Earnings Call Highlights PKU Pivot
PremiumCompany Announcements
Beam Therapeutics Earnings Call Highlights PKU Pivot
2M ago
BEAM
Beam Therapeutics: Advancing Interventional Genetics With Strong Balance Sheet and Multiple Near-Term Catalysts Supporting Buy Rating
PremiumRatingsBeam Therapeutics: Advancing Interventional Genetics With Strong Balance Sheet and Multiple Near-Term Catalysts Supporting Buy Rating
2M ago
BEAM
Beam Therapeutics price target raised to $26 from $22 at RBC Capital
Premium
The Fly
Beam Therapeutics price target raised to $26 from $22 at RBC Capital
2M ago
BEAM
Beam Therapeutics price target raised to $65 from $57 at Wedbush
Premium
The Fly
Beam Therapeutics price target raised to $65 from $57 at Wedbush
2M ago
BEAM
Beam Therapeutics price target raised to $75 from $74 at Canaccord
PremiumThe Fly
Beam Therapeutics price target raised to $75 from $74 at Canaccord
2M ago
BEAM
Beam Therapeutics: Clinical Momentum, Platform Validation, and De‑Risked Financing Support Buy Rating and $47 Target
PremiumRatings
Beam Therapeutics: Clinical Momentum, Platform Validation, and De‑Risked Financing Support Buy Rating and $47 Target
2M ago
BEAM
Beam Therapeutics price target raised to $47 from $45 at BofA
PremiumThe Fly
Beam Therapeutics price target raised to $47 from $45 at BofA
3M ago
PFE
BEAM
Kyverna Therapeutics appoints Sravan Emany, Andrew Miller to board
PremiumThe Fly
Kyverna Therapeutics appoints Sravan Emany, Andrew Miller to board
3M ago
BEAM
KYTX
Beam Therapeutics announces $500M financing facility
PremiumThe FlyBeam Therapeutics announces $500M financing facility
3M ago
BEAM
Beam Therapeutics Secures $500 Million Credit Facility
Premium
Company Announcements
Beam Therapeutics Secures $500 Million Credit Facility
3M ago
8K
BEAM
Beam Therapeutics reports Q4 EPS $2.33 vs ($1.09) last year
Premium
The Fly
Beam Therapeutics reports Q4 EPS $2.33 vs ($1.09) last year
3M ago
BEAM

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >